Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer.

ABSTRACT: Risk factors for colorectal cancer (CRC) include proinflammatory diets, sedentary habits, and obesity, in addition to genetic syndromes that predispose individuals to this disease. Current treatment relies on surgical excision and cytotoxic chemotherapies. There has been a renewed interest in immunotherapy as a treatment option for CRC given the success in melanoma and microsatellite instable (MSI) CRC. Immunotherapy with checkpoint inhibitors only plays a role in the 4%-6% of patients with MSIhigh tumors and even within this subpopulation, response rates can vary from 30% to 50%. Most patients with CRC do not respond to this modality of treatment, even though colorectal tumors are frequently infiltrated with T cells. Tumor cells limit apoptosis and survive following intensive chemotherapy

SUBMITTER: Mendonca Gorgulho C 

PROVIDER: S-EPMC8092416 | biostudies-literature | 2021 Feb-Mar 01

REPOSITORIES: biostudies-literature